The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
International Peripheral T-Cell and Natural Killer/T-Cell Lymphoma Study: Pathology Findings and Clinical Outcomes
Abstract
Purpose: Peripheral T-cell lymphoma (PTCL) and natural killer/T-cell lymphoma (NKTCL) are rare and heterogeneous forms of non-Hodgkin's lymphoma (NHL) that, in general, are associated with a poor clinical outcome. Patients and Methods: A cohort of 1,314 cases of PTCL and NKTCL was organized from 22 centers worldwide, consisting of patients with previously untreated PTCL or NKTCL who were diagnosed between 1990 and 2002. Tissue biopsies, immunophenotypic markers, molecular genetic studies, and clinical information from consecutive patients at each site were reviewed by panels of four expert hematopathologists and classified according to the WHO classification. Results: A diagnosis of PTCL or NKTCL was confirmed in 1,153 (87.8%) of the cases. The most common subtypes were PTCL not otherwise specified (NOS; 25.9%), angioimmunoblastic type (18.5%), NKTCL (10.4%), and adult T-cell leukemia/lymphoma (ATLL; 9.6%). Misclassification occurred in 10.4% of the cases including Hodgkin's lymphoma (3%), B-cell lymphoma (1.4%), unclassifiable lymphoma (2.8%), or a diagnosis other than lymphoma (2.3%). We found marked variation in the frequency of the various subtypes by geographic region. The use of an anthracycline-containing regimen was not associated with an improved outcome in PTCL-NOS or angioimmunoblastic type, but was associated with an improved outcome in anaplastic large-cell lymphoma, ALK positive. Conclusion: The WHO classification is useful for defining subtypes of PTCL and NKTCL. However, expert hematopathology review is important for accurate diagnosis. The clinical outcome for patients with most of these lymphoma subtypes is poor with standard therapies, and novel agents and new modalities are needed to improve survival.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Regression Models and Life-Tables
Cox, D. R. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_37 · Cited by 26,297
Harris, N., Jaffe, E., Stein, H., Banks, P., Chan, J., Cleary, M., Delsol, G., De Wolf- Peeters, C., Falini, B., & Gatter, K. (1994) · Blood · doi:10.1182/blood.v84.5.1361.1361 · Cited by 6,327
A Predictive Model for Aggressive Non-Hodgkin's Lymphoma
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291402 · Cited by 4,949
Hossfeld, D. K. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf146 · Cited by 4,625
The Non-Hodgkin's Lymphoma Pathologic Classification Project (1982) · Cancer · doi:10.1002/1097-0142(19820515)49:10<2112::aid-cncr2820491024>3.0.co;2-2 · Cited by 3,059
The Non-Hodgkin's Lymphoma Classification Project (1997) · Blood · doi:10.1182/blood.v89.11.3909 · Cited by 2,461
Immunologic characterization of human malignant lymphomas
Lukes, R. J., & Collins, R. D. (1974) · Cancer · doi:10.1002/1097-0142(197410)34:8+<1488::aid-cncr2820340822>3.0.co;2-c · Cited by 1,092
Cited by
Campo, E., Swerdlow, S. H., Harris, N. L., Pileri, S., Stein, H., & Jaffe, E. S. (2011) · Blood · doi:10.1182/blood-2011-01-293050 · Cited by 2,008
Armitage, J. O., Gascoyne, R. D., Lunning, M. A., & Cavalli, F. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32407-2 · Cited by 1,176
Horwitz, S., O'Connor, O. A., Pro, B., Illidge, T., Fanale, M., Advani, R., Bartlett, N. L., Christensen, J. H., Morschhauser, F., Domingo-Domenech, E., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32984-2 · Cited by 739
Au, W.-Y., Weisenburger, D. D., Intragumtornchai, T., Nakamura, S., Kim, W.-S., Sng, I., Vose, J., Armitage, J. O., Liang, R., & for the International Peripheral T-Cell Lymphoma Project (2009) · Blood · doi:10.1182/blood-2008-10-185256 · Cited by 736
Coiffier, B., Pro, B., Prince, H. M., Foss, F., Sokol, L., Greenwood, M., Caballero, D., Borchmann, P., Morschhauser, F., Wilhelm, M., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.37.4223 · Cited by 680
Ishida, T., Joh, T., Uike, N., Yamamoto, K., Utsunomiya, A., Yoshida, S., Saburi, Y., Miyamoto, T., Takemoto, S., Suzushima, H., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.37.3472 · Cited by 657
O'Connor, O. A., Pro, B., Pinter-Brown, L., Bartlett, N., Popplewell, L., Coiffier, B., Jo Lechowicz, M., Savage, K. J., Shustov, A. R., Gisselbrecht, C., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.29.9024 · Cited by 647
Shankland, K. R., Armitage, J. O., & Hancock, B. W. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60605-9 · Cited by 641
Up-Front Autologous Stem-Cell Transplantation in Peripheral T-Cell Lymphoma: NLG-T-01
d'Amore, F., Relander, T., Lauritzsen, G. F., Jantunen, E., Hagberg, H., Anderson, H., Holte, H., Österborg, A., Merup, M., Brown, P., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.2719 · Cited by 594
O'Connor, O. A., Horwitz, S., Masszi, T., Van Hoof, A., Brown, P., Doorduijn, J., Hess, G., Jurczak, W., Knoblauch, P., Chawla, S., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.2782 · Cited by 555
Iqbal, J., Wright, G., Wang, C., Rosenwald, A., Gascoyne, R. D., Weisenburger, D. D., Greiner, T. C., Smith, L., Guo, S., Wilcox, R. A., et al. (2014) · Blood · doi:10.1182/blood-2013-11-536359 · Cited by 552
Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma
Piekarz, R. L., Frye, R., Prince, H. M., Kirschbaum, M. H., Zain, J., Allen, S. L., Jaffe, E. S., Ling, A., Turner, M., Peer, C. J., et al. (2011) · Blood · doi:10.1182/blood-2010-10-312603 · Cited by 488
Lemonnier, F., Couronné, L., Parrens, M., Jaïs, J.-P., Travert, M., Lamant, L., Tournillac, O., Rousset, T., Fabiani, B., Cairns, R. A., et al. (2012) · Blood · doi:10.1182/blood-2012-02-408542 · Cited by 455
Crescenzo, R., Abate, F., Lasorsa, E., Tabbo’, F., Gaudiano, M., Chiesa, N., Di Giacomo, F., Spaccarotella, E., Barbarossa, L., Ercole, E., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.03.006 · Cited by 443
Mak, V., Hamm, J., Chhanabhai, M., Shenkier, T., Klasa, R., Sehn, L. H., Villa, D., Gascoyne, R. D., Connors, J. M., & Savage, K. J. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.7524 · Cited by 437
Weisenburger, D. D., Savage, K. J., Harris, N. L., Gascoyne, R. D., Jaffe, E. S., MacLennan, K. A., Rüdiger, T., Pileri, S., Nakamura, S., Nathwani, B., et al. (2011) · Blood · doi:10.1182/blood-2010-09-310342 · Cited by 431
A targeted mutational landscape of angioimmunoblastic T-cell lymphoma
Odejide, O., Weigert, O., Lane, A. A., Toscano, D., Lunning, M. A., Kopp, N., Kim, S., van Bodegom, D., Bolla, S., Schatz, J. H., et al. (2014) · Blood · doi:10.1182/blood-2013-10-531509 · Cited by 398
Iqbal, J., Weisenburger, D. D., Greiner, T. C., Vose, J. M., McKeithan, T., Kucuk, C., Geng, H., Deffenbacher, K., Smith, L., Dybkaer, K., et al. (2010) · Blood · doi:10.1182/blood-2009-06-227579 · Cited by 392
Shi, Y., Dong, M., Hong, X., Zhang, W., Feng, J., Zhu, J., Yu, L., Ke, X., Huang, H., Shen, Z., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv237 · Cited by 385
A recurrent inactivating mutation in RHOA GTPase in angioimmunoblastic T cell lymphoma
Yoo, H. Y., Sung, M. K., Lee, S. H., Kim, S., Lee, H., Park, S., Kim, S. C., Lee, B., Rho, K., Lee, J.-E., et al. (2014) · Nature Genetics · doi:10.1038/ng.2916 · Cited by 380
Ogura, M., Ishida, T., Hatake, K., Taniwaki, M., Ando, K., Tobinai, K., Fujimoto, K., Yamamoto, K., Miyamoto, T., Uike, N., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.52.0924 · Cited by 362
Yamamoto, K., Utsunomiya, A., Tobinai, K., Tsukasaki, K., Uike, N., Uozumi, K., Yamaguchi, K., Yamada, Y., Hanada, S., Tamura, K., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.3575 · Cited by 354
Foss, F. M., Zinzani, P. L., Vose, J. M., Gascoyne, R. D., Rosen, S. T., & Tobinai, K. (2011) · Blood · doi:10.1182/blood-2010-05-231548 · Cited by 353
Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin
Horwitz, S. M., Advani, R. H., Bartlett, N. L., Jacobsen, E. D., Sharman, J. P., O’Connor, O. A., Siddiqi, T., Kennedy, D. A., & Oki, Y. (2014) · Blood · doi:10.1182/blood-2013-12-542142 · Cited by 352
Oncogenic activation of the STAT3 pathway drives PD-L1 expression in natural killer/T-cell lymphoma
Song, T. L., Nairismägi, M.-L., Laurensia, Y., Lim, J.-Q., Tan, J., Li, Z.-M., Pang, W.-L., Kizhakeyil, A., Wijaya, G.-C., Huang, D.-C., et al. (2018) · Blood · doi:10.1182/blood-2018-01-829424 · Cited by 326
Huang, Y., de Reyniès, A., de Leval, L., Ghazi, B., Martin-Garcia, N., Travert, M., Bosq, J., Brière, J., Petit, B., Thomas, E., et al. (2010) · Blood · doi:10.1182/blood-2009-05-221275 · Cited by 313
Dreyling, M., Thieblemont, C., Gallamini, A., Arcaini, L., Campo, E., Hermine, O., Kluin-Nelemans, J. C., Ladetto, M., Le Gouill, S., Iannitto, E., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mds643 · Cited by 311
Targeting the T cell receptor β-chain constant region for immunotherapy of T cell malignancies
Maciocia, P. M., Wawrzyniecka, P. A., Philip, B., Ricciardelli, I., Akarca, A. U., Onuoha, S. C., Legut, M., Cole, D. K., Sewell, A. K., Gritti, G., et al. (2017) · Nature Medicine · doi:10.1038/nm.4444 · Cited by 286
Janus Kinase 3–Activating Mutations Identified in Natural Killer/T-cell Lymphoma
Koo, G. C., Tan, S. Y., Tang, T., Poon, S. L., Allen, G. E., Tan, L., Chong, S. C., Ong, W. S., Tay, K., Tao, M., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0028 · Cited by 275
Genetic drivers of oncogenic pathways in molecular subgroups of peripheral T-cell lymphoma
Heavican, T. B., Bouska, A., Yu, J., Lone, W., Amador, C., Gong, Q., Zhang, W., Li, Y., Dave, B. J., Nairismägi, M.-L., et al. (2019) · Blood · doi:10.1182/blood-2018-09-872549 · Cited by 275
Watatani, Y., Sato, Y., Miyoshi, H., Sakamoto, K., Nishida, K., Gion, Y., Nagata, Y., Shiraishi, Y., Chiba, K., Tanaka, H., et al. (2019) · Leukemia · doi:10.1038/s41375-019-0473-1 · Cited by 195
Izutsu, K., Makita, S., Nosaka, K., Yoshimitsu, M., Utsunomiya, A., Kusumoto, S., Morishima, S., Tsukasaki, K., Kawamata, T., Ono, T., et al. (2023) · Blood · doi:10.1182/blood.2022016862 · Cited by 167
Ishida, T., Fujiwara, H., Nosaka, K., Taira, N., Abe, Y., Imaizumi, Y., Moriuchi, Y., Jo, T., Ishizawa, K., Tobinai, K., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.7732 · Cited by 152
Phillips, A. A., Fields, P. A., Hermine, O., Ramos, J. C., Beltran, B. E., Pereira, J., Wandroo, F., Feldman, T., Taylor, G. P., Sawas, A., et al. (2019) · Haematologica · doi:10.3324/haematol.2018.205096 · Cited by 70
Dasatinib is an effective treatment for angioimmunoblastic t-cell lymphoma
Nguyen, T. B., Sakata-Yanagimoto, M., Fujisawa, M., Nuhat, S. T., Miyoshi, H., Nannya, Y., Hashimoto, K., Fukumoto, K., Bernard, O. A., Kiyoki, Y., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-2787 · Cited by 56
Holst, J. M., Plesner, T. L., Pedersen, M. B., Frederiksen, H., Møller, M. B., Clausen, M. R., Hansen, M. C., Hamilton-Dutoit, S. J., Nørgaard, P., Johansen, P., et al. (2019) · Haematologica · doi:10.3324/haematol.2019.225839 · Cited by 25
Metadata
- Authors
- International T-Cell Lymphoma Project
- Venue
- Journal of Clinical Oncology
- Published
- 2008-09-01
- Volume
- 26
- Issue
- 25
- Pages
- 4124-4130
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2416844197
- Cited by
- 2,108
- References
- 26
- FWCI
- 43.39
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.